AcquisitionOther
Intra-Cellular Therapies, Inc. acquired target
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Intra-Cellular Therapies, Inc. -> target · $132.00
FDA for CAPLYTA ® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA ® has potential to become a standard of care for most common depressive disorders CAPLYTA ® adds to Johnson & Johnsons robust lineup of therapies with $5
Open source record (SEC) ↗